Carregant...
Aprepitant for prevention of nausea and vomiting secondary to high-dose Cyclophosphamide administered to patients undergoing Autologous Peripheral Blood Stem Cells mobilization: A Phase II Trial
This is a phase II trial evaluating efficacy and safety of Aprepitant (AP) in combination with 5-HT3 antagonist and adjusted dose dexamethasone in patients receiving high-dose cyclophosphamide (CY) and filgrastim for stem cell mobilization. We used Simon’s optimal two-stage design constrained to few...
Guardat en:
| Autors principals: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3594089/ https://ncbi.nlm.nih.gov/pubmed/22193771 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00520-011-1341-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|